Lori S Muffly, MD
Hematopoietic Cell Transplantation and Cellular Therapy · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Muffly’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A132153 · Current
Licensed to practise in California · since 2014 · expires 2028-02-29 · Jefferson Medical College of Thomas Jefferson University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Colorado DR.52339Physician · since 2013 · expires 2015-04-30Specialty on the licence: Oncology/HematologyExpiredNo board action on this licenceCheck it with the stateWhat they told the state about themselves
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$43,299
Medicare paid this office $43,299 for 77 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $20,969 | $104 |
| Long return visit (40+ min) | 41 | $12,796 | $120 |
| Long return visit (40+ min) | 20 | $5,740 | $155 |
Who their Medicare patients are
77 Original Medicare patients in 2024. Average age 67 · Under 65 16% · 85 and older 0% · Women 46% · Also on Medicaid 17% · Health risk score 3.40. Above the middle of the specialty; the typical hematopoietic cell transplantation and cellular therapy clinician is at 2.85.
Conditions among them: High blood pressure 53% · Coronary heart disease 22% · Chronic kidney disease 22% · Atrial fibrillation 22% · Diabetes 19% · COPD 19% · Depression 17% · Cancer 14%.
The office billed $157,430, Medicare allowed $57,263 and paid $43,299; for 381 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 77 | 381 | 67 | 3.40 | $157,430 | $43,299 |
| 2023 | 84 | 415 | 67 | 3.49 | $160,226 | $49,553 |
| 2022 | 68 | 273 | 67 | 3.32 | $128,738 | $29,910 |
| 2021 | 59 | 344 | 63 | 3.25 | $153,987 | $37,249 |
| 2020 | 67 | 316 | 65 | 3.65 | $155,057 | $32,727 |
| 2019 | 78 | 329 | 66 | 3.46 | $142,319 | $33,317 |
| 2018 | 80 | 465 | 65 | 3.54 | $180,728 | $45,271 |
| 2017 | 96 | 478 | 65 | 3.56 | $242,264 | $47,377 |
| 2016 | 62 | 391 | 63 | 3.09 | $176,401 | $38,322 |
| 2015 | 51 | 261 | 67 | 3.29 | $107,332 | $24,775 |
| 2014 | 188 | 13,805 | 66 | 3.31 | $644,762 | $185,093 |
| 2013 | 17 | 132 | 60 | 2.12 | $32,740 | $10,927 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Long return visit (40+ min) | 56 | $24,508 | $129 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $19,320 | $109 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,285 | $107 |
2022: 4 services
| Long return visit (40+ min) | 44 | $13,966 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $10,352 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,037 | $170 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,270 | $98 |
2021: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $18,734 | $96 |
| Long return visit (40+ min) | 35 | $13,540 | $119 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,406 | $185 |
2020: 2 services
| Long return visit (40+ min) | 50 | $15,186 | $102 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $12,594 | $98 |
2019: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $15,942 | $94 |
| Long return visit (40+ min) | 41 | $10,568 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,386 | $184 |
| Hospital discharge day management, more than 30 minutes | 18 | $1,884 | $99 |
2018: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $25,184 | $94 |
| Long return visit (40+ min) | 41 | $12,682 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $3,093 | $182 |
| Hospital discharge day management, more than 30 minutes | 19 | $1,876 | $99 |
2017: 4 services
| Long return visit (40+ min) | 67 | $23,455 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $14,022 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,371 | $177 |
| Hospital discharge day management, more than 30 minutes | 19 | $1,964 | $98 |
2016: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $19,418 | $91 |
| Long return visit (40+ min) | 35 | $10,748 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $3,264 | $172 |
| Hospital discharge day management, more than 30 minutes | 16 | $1,620 | $95 |
2015: 3 services
| Long return visit (40+ min) | 30 | $10,217 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $9,810 | $93 |
| Return visit (30+ min) | 14 | $2,519 | $70 |
2014: 19 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $36,581 | $83 |
| Long return visit (40+ min) | 44 | $10,801 | $111 |
| Administration of chemotherapy into vein, 1 hour or less | 18 | $3,051 | $105 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 22 | $2,922 | $53 |
| Magnesium level | 114 | $2,113 | $9 |
| Return visit (30+ min) | 24 | $2,097 | $75 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $1,600 | $57 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 86 | $1,518 | $9 |
| Blood test, comprehensive group of blood chemicals | 115 | $1,356 | $6 |
| Lactate dehydrogenase (enzyme) level | 109 | $590 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 15 | $584 | $14 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 52 | $571 | $7 |
| Glutamyltransferase (liver enzyme) level | 100 | $542 | $2 |
| Injection of additional new drug or substance into vein | 14 | $473 | $18 |
| Uric acid level, blood | 109 | $467 | $2 |
| Phosphate level | 110 | $450 | $2 |
| Microscopic examination for white blood cells with manual cell count | 52 | $394 | $5 |
| Injection of drug or substance under skin or into muscle | 12 | $356 | $20 |
| Insertion of needle into vein for collection of blood sample | 69 | $270 | $3 |
2013: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $9,152 | $79 |
Medicaid work
$37,139 in 2024
Medicaid paid $37,139 for 195 billed services this clinician did in 2024, up to 25 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 195 | $37,139 |
| 2024 | 195 | 1 | 25 | $37,139 |
| 2023 | 336 | 1 | 28 | $25,041 |
| 2022 | 274 | 1 | 27 | $24,190 |
| 2021 | 187 | 1 | 21 | $15,021 |
| 2020 | 147 | 1 | 18 | $8,853 |
| 2019 | 130 | 2 | 21 | $7,391 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 336 | $25,041 |
2022
| Long return visit (40+ min) | 274 | $24,190 |
2021
| Long return visit (40+ min) | 187 | $15,021 |
2020
| Long return visit (40+ min) | 147 | $8,853 |
2019
| Long return visit (40+ min) | 89 | $5,198 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 41 | $2,193 |
Drugs they prescribed that Part D paid
$2,127,541
Pharmacies billed $2,127,541 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
311 generic and fewer than 11 brand-name prescriptions · $2,127,541 in drug cost · 52 antibiotic prescriptions to 17 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jakafi | 111 | $1,345,867 | $12,125 |
| Rezurock | 24 | $453,277 | $18,887 |
| Posaconazole | 16 | $16,391 | $1,024 |
| Acyclovir | 106 | $2,367 | $22 |
| Tacrolimus | 11 | $734 | $67 |
See all 7 drugs
| Jakafi | 111 | $1,345,867 | $12,125 |
| Rezurock | 24 | $453,277 | $18,887 |
| Posaconazole | 16 | $16,391 | $1,024 |
| Acyclovir | 106 | $2,367 | $22 |
| Tacrolimus | 11 | $734 | $67 |
| Sulfamethoxazole-Trimethoprim | 37 | $290 | $8 |
| Prednisone | 20 | $137 | $7 |
Year by year
| 2024 | 466 | 54 | None | None | $2,127,541 |
| 2023 | 443 | 50 | None | None | $1,238,258 |
| 2022 | 520 | 50 | None | 22% | $1,443,812 |
| 2021 | 407 | 44 | None | 24% | $1,016,652 |
| 2020 | 431 | 32 | 4% (18) | 14% | $548,946 |
| 2019 | 344 | 40 | None | None | $305,111 |
| 2018 | 476 | 52 | None | None | $402,113 |
| 2017 | 382 | 53 | None | None | $311,245 |
| 2016 | 285 | 37 | 4% (11) | 16% | $201,005 |
| 2015 | 177 | 27 | None | None | $93,883 |
| 2014 | 189 | 37 | 10% (18) | 18% | $33,016 |
| 2013 | 120 | 18 | None | 13% | $6,579 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Jakafi | 60 | $717,249 | $11,954 |
| Acyclovir | 110 | $2,768 | $25 |
| Tacrolimus | 21 | $1,027 | $49 |
| Dexamethasone | 13 | $501 | $39 |
| Hydrocortisone | 15 | $486 | $32 |
| Prednisone | 22 | $245 | $11 |
| Sulfamethoxazole-Trimethoprim | 25 | $179 | $7 |
| Gabapentin | 13 | $134 | $10 |
2022: 11 drugs
| Jakafi | 76 | $1,034,949 | $13,618 |
| Atovaquone | 24 | $13,373 | $557 |
| Acyclovir | 132 | $3,197 | $24 |
| Ursodiol | 14 | $2,673 | $191 |
| Dexamethasone | 22 | $1,087 | $49 |
| Triamcinolone Acetonide | 12 | $382 | $32 |
| Fluconazole | 12 | $268 | $22 |
| Pantoprazole | 16 | $257 | $16 |
| Sulfamethoxazole-Trimethoprim | 25 | $225 | $9 |
| Prednisone | 21 | $209 | $10 |
| Lorazepam | 12 | $99 | $8 |
2021: 9 drugs
| Jakafi | 70 | $860,961 | $12,299 |
| Atovaquone | 21 | $12,901 | $614 |
| Acyclovir | 84 | $2,036 | $24 |
| Dexamethasone | 24 | $1,714 | $71 |
| Fluconazole | 18 | $970 | $54 |
| Nystatin | 11 | $518 | $47 |
| Triamcinolone Acetonide | 11 | $344 | $31 |
| Levothyroxine | 12 | $191 | $16 |
| Sulfamethoxazole-Trimethoprim | 11 | $149 | $14 |
2020: 10 drugs
| Jakafi | 32 | $439,221 | $13,726 |
| Tacrolimus | 29 | $2,925 | $101 |
| Dexamethasone | 19 | $2,393 | $126 |
| Acyclovir | 79 | $1,845 | $23 |
| Fluconazole | 17 | $1,049 | $62 |
| Nystatin | 18 | $657 | $36 |
| Triamcinolone Acetonide | 11 | $377 | $34 |
| Prednisone | 27 | $374 | $14 |
| Sulfamethoxazole-Trimethoprim | 23 | $232 | $10 |
| Levofloxacin | 11 | $173 | $16 |
2019: 7 drugs
| Noxafil | 11 | $67,389 | $6,126 |
| Acyclovir | 63 | $4,430 | $70 |
| Tacrolimus | 21 | $1,755 | $84 |
| Dexamethasone | 15 | $853 | $57 |
| Prednisone | 35 | $353 | $10 |
| Sulfamethoxazole-Trimethoprim | 29 | $168 | $6 |
| Pantoprazole | 11 | $68 | $6 |
2018: 9 drugs
| Imbruvica | 13 | $145,149 | $11,165 |
| Noxafil | 15 | $81,669 | $5,445 |
| Acyclovir | 90 | $3,514 | $39 |
| Tacrolimus | 17 | $1,178 | $69 |
| Prednisone | 31 | $485 | $16 |
| Sulfamethoxazole-Trimethoprim | 33 | $324 | $10 |
| Pantoprazole | 11 | $94 | $9 |
| Lisinopril | 11 | $43 | $4 |
| Amlodipine Besylate | 17 | $41 | $2 |
2017: 7 drugs
| Iclusig | 12 | $201,294 | $16,774 |
| Acyclovir | 82 | $1,517 | $18 |
| Mycophenolate Mofetil | 13 | $805 | $62 |
| Tacrolimus | 15 | $458 | $31 |
| Sulfamethoxazole-Trimethoprim | 27 | $195 | $7 |
| Levothyroxine | 12 | $130 | $11 |
| Amlodipine Besylate | 11 | $36 | $3 |
2016: 4 drugs
| Noxafil | 12 | $83,901 | $6,992 |
| Acyclovir | 44 | $1,113 | $25 |
| Sulfamethoxazole-Trimethoprim | 25 | $254 | $10 |
| Ranitidine | 13 | $113 | $9 |
2015: 3 drugs
| Voriconazole | 13 | $7,687 | $591 |
| Acyclovir | 29 | $697 | $24 |
| Mycophenolate Mofetil | 11 | $449 | $41 |
2014: 2 drugs
| Ursodiol | 13 | $1,162 | $89 |
| Acyclovir | 28 | $540 | $19 |
2013: 2 drugs
| Acyclovir | 17 | $260 | $15 |
| Levothyroxine | 12 | $117 | $10 |
Money from drug and device companies
$23,050 in 2025
| 2025 | 7 | 22 | $18,480 | $23,050 |
| 2024 | 5 | 13 | $5,068 | $7,788 |
| 2023 | 8 | 20 | $15,740 | $16,773 |
| 2022 | 3 | 7 | $8,545 | $8,710 |
| 2021 | 8 | 17 | $26,456 | $26,753 |
| 2020 | 1 | 2 | $3,250 | $3,250 |
| 2019 | 2 | 4 | None | $273 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Incyte | Niktimvo | $7,739 | 5 payments
|
| Autolus | None | $5,775 | 2 payments
|
| Gilead Sciences | None | $5,452 | 2 payments
|
| National Marrow Donor Program | None | $3,338 | 9 payments
|
| Astellas Pharma Global Development | Xospata | $620 | 1 payment
|
| Merck Sharp & Dohme | None | $81 | 2 payments
|
See all 22 published payments
| Incyte | Consulting · 2025-12-18 | Niktimvo | $3,425 |
| Merck Sharp & Dohme | Meals · 2025-12-05 | None | $60 |
| Merck Sharp & Dohme | Meals · 2025-12-05 | None | $22 |
| Autolus | Honoraria · 2025-12-05 | None | $5,558 |
| Autolus | Meals · 2025-12-05 | None | $218 |
| Incyte | Meals · 2025-12-04 | Niktimvo | $122 |
| Incyte | Meals · 2025-12-04 | Niktimvo | $26 |
| National Marrow Donor Program | Gift · 2025-12-01 | None | $75 |
| Astellas Pharma Global Development | Consulting · 2025-11-21 | Xospata | $620 |
| National Marrow Donor Program | Travel · 2025-10-31 | None | $158 |
| Janssen Biotech | Meals · 2025-10-18 | Carvykti | $44 |
| National Marrow Donor Program | Meals · 2025-10-10 | None | $222 |
| National Marrow Donor Program | Meals · 2025-09-25 | None | $301 |
| National Marrow Donor Program | Travel · 2025-09-25 | None | $447 |
| National Marrow Donor Program | Travel · 2025-09-24 | None | $1,041 |
| Incyte | Consulting · 2025-07-31 | Niktimvo | $3,425 |
| Gilead Sciences | Consulting · 2025-07-10 | None | $4,002 |
| National Marrow Donor Program | Meals · 2025-06-13 | None | $103 |
| Incyte | Travel · 2025-04-24 | Niktimvo | $741 |
| National Marrow Donor Program | Meals · 2025-01-30 | None | $311 |
| National Marrow Donor Program | Travel · 2025-01-30 | None | $680 |
| Gilead Sciences | Consulting · 2025-01-13 | None | $1,450 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $7,788
| National Marrow Donor Program | None | $2,588 | 8 payments
|
| Incyte | None | $2,398 | 1 payment
|
| Medexus Pharma | None | $2,040 | 1 payment
|
| Pfizer | Besponsa | $692 | 2 payments
|
| Kite Pharma | None | $70 | 1 payment
|
2023: $16,773
| Adaptive Biotechnologies | Clonoseq | $4,806 | 10 payments
|
| Pfizer | Cibinqo | $4,590 | 2 payments
|
| Kite Pharma | Tecartus | $4,020 | 1 payment
|
| Astellas Pharma Global Development | Xospata | $2,480 | 1 payment
|
| National Marrow Donor Program | None | $510 | 2 payments
|
| Celgene | Onureg | $250 | 2 payments
|
| Jazz Pharmaceuticals | Rylaze | $100 | 1 payment
|
| Amgen | Blincyto | $18 | 1 payment
|
2022: $8,710
| Kite Pharma | Tecartus | $4,800 | 4 payments
|
| Adaptive Biotechnologies | Clonoseq | $3,290 | 2 payments
|
| Astellas Pharma Global Development | Xospata | $620 | 1 payment
|
2021: $26,753
| Adaptive Biotechnologies | Clonoseq | $8,347 | 5 payments
|
| Pfizer | Besponsa | $7,290 | 2 payments
|
| Kite Pharma | Tecartus | $4,125 | 4 payments
|
| Amgen | Blincyto | $2,596 | 1 payment
|
| Astellas Pharma Global Development | Xospata | $2,170 | 2 payments
|
| Jazz Pharmaceuticals | Rylaze | $2,100 | 1 payment
|
| Celgene | Onureg | $100 | 1 payment
|
| CSL Behring | Hizentra | $25 | 1 payment
|
2020: $3,250
| Amgen | Blincyto | $3,250 | 2 payments
|
2019: $273
| Novartis Pharmaceuticals | Kymriah | $153 | 2 payments
|
| Amgen | Blincyto | $120 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Kite Pharma, Inc. · Understanding Patient Access To Car-T Therapy, Scoping Phase 1 · 2025 | Their institution | $661,940 |
| Kite Pharma, Inc. · Phase 1b Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia · 2024 | Their institution | $285,650 |
| Kite Pharma, Inc. · Real World Outcomes Collaborative of Car T-Cell Therapies in Adult Acute Lymphoblastic Leukemia (Rocca) · 2025 | Their institution | $250,000 |
| Astellas Pharma Global Development · A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Trial of the Flt3 Inhibitor Gilteritinib Administered As Maintenance Therapy Following Allogeneic Transplant for Patients With Flt3itd Aml · 2019 | Their institution | $161,180 |
| Kite Pharma, Inc. · Isr: Phase 1b Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia · 2025 | Their institution | $154,325 |
| Kite Pharma, Inc. · Isr-Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia · 2023 | Their institution | $129,775 |
| Servier Affaires Medicales · Evaluation of Health Burden in Adolescent and Young Adult Survivors of Acute Lymphoblastic Leukemia Therapy · 2019 | Their institution | $87,988 |
| Adaptive Biotechnologies Corporation · Clonoseq · 2019 | Their institution | $57,541 |
| Adaptive Biotechnologies Corporation · Clonoseq · 2020 | Their institution | $55,418 |
| Adaptive Biotechnologies Corporation · Watch Registry · 2021 | Their institution | $53,009 |
| Kite Pharma, Inc. · A Phase 1 Open-Label, Multicenter Study Evaluating the Safety of Kite 222, An Autologous Anti-Cll-1 Car T Cell Therapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (Aml) · 2021 | Their institution | $32,243 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study To Assess the Efficacy and Safety of Shp620 Compared To Valganciclovir for the Treatment of Cytomegalovirus (Cmv) Infection in Stem Cell Transplant Recipients · 2023 | Their institution | $20,263 |
| Astellas Pharma Global Development · A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Trial of the Flt3 Inhibitor Gilteritinib Administered As Maintenance Therapy Following Allogeneic Transplant for Patients With Flt3/Itd Aml · 2020 | Their institution | $17,570 |
| Incyte Corporation · Access-T: Phase 1 Trial for Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation From An Hla-Mismatched Donor (7/8) With Orca-T · 2025 | Their institution | $15,680 |
| Novartis Pharmaceuticals Corporation · Phase I, Open Label, Multicenter, Dose Escalation Study of Ytb323 in Adult Patients With Cll/Sll and Dlbcl · 2023 | Their institution | $8,467 |
| National Marrow Donor Program · Molecular Evaluation of Aml Patients After Stem Cell Transplant To Understand Relapse Events · 2024 | Their institution | $8,114 |
| National Marrow Donor Program · Molecular Evaluation of Aml Patients After Stem Cell Transplant To Understand Relapse Events (Measure) · 2023 | Their institution | $7,501 |
| Astellas Pharma Global Development · A Retrospective Cohort Study of the Persistence of Flt3- Tyrosine Kinase Inhibitor Therapy in Acute Myeloid Leukemia Patients · 2022 | This clinician | $6,902 |
| National Marrow Donor Program · Molecular Evaluation of Aml Patients After Stem Cell Transplant To Understand Relapse Events (Measure) · 2025 | Their institution | $6,333 |
| Astellas Pharma Global Development · Utilization Patterns Post Approval of Gilteritinib in US in R/R Flt3+ Aml · 2022 | This clinician | $5,577 |
| National Marrow Donor Program · Molecular Evaluation of Aml Patients After Stem Cell Transplant To Understand Relapse Events (Measure) · 2024 | Their institution | $3,243 |
| Astellas Pharma Global Development · Utilization Patterns Post Approval of Gilteritinib in US in R/R Flt3+ Aml · 2021 | This clinician | $2,173 |
| Astellas Pharma Global Development · A Retrospective Cohort Study of Healthcare Resource Use (Hru) and Economic Burden in Patients Newly Diagnosed With Acute Myeloid Leukemia (Aml) Who Received Post Hematopoietic Stem-Cell Transplantation (Post-Hsct) Maintenance Treatment With Midostaurin and Sorafenib in A Real-World Dataset the United States · 2023 | This clinician | $2,166 |
| Astellas Pharma Global Development · A Retrospective Cohort Study of Healthcare Resource Use (Hru) and Economic Burden in Patients Newly Diagnosed With Acute Myeloid Leukemia (Aml) Who Received Post Hematopoietic Stem-Cell Transplantation (Post-Hsct) Maintece Treatment With Midostaurin A · 2022 | This clinician | $2,026 |
| Novartis Pharmaceuticals Corporation · Phase I, Open Label, Multicenter, Dose Escalation Study of Ytb323 in Adult Patients With Cll/Sll and Dlbcl · 2022 | Their institution | $1,998 |
| CSL Behring · A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (Aat) Combined With Corticosteroids Vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-Versus-Host Disease (Gvhd) Following Allogeneic Hematopoietic Stem Cell Transplant · 2020 | Their institution | $1,569 |
| Novartis Pharmaceuticals Corporation · Phase I, Open Label, Multicenter, Dose Escalation Study of Ytb323 in Adult Patients With Cll/Sll and Dlbcl · 2024 | Their institution | $1,425 |
| National Marrow Donor Program · A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Trial of the Flt3 Inhibitor Gilteritinib Administered As Maintenance Therapy Following Allogeneic Transplant for Patients With Flt3/Itd Aml · 2023 | Their institution | $1,118 |
| National Marrow Donor Program · Facilitating Activation of Study Trials (Fast) · 2025 | Their institution | $1,000 |
| Astellas Pharma Global Development · Retrospective Observational Study Examining Clinical Outcomes and Treatment Patterns in Patients With Fms-Like Tyrosine Kinase 3 Mutation-Positive Acute Myeloid Leukemia (Flt3mut+Aml) Undergoing Allogeneic Hematopoietic Cell Transplantation (Allohct) in the United States and Canada · 2023 | This clinician | $925 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1427256254
- Licence
- CA A132153, CO DR.0052339, NH RT1744California A132153: Current · expires 2028-02-29Colorado DR.52339: Expired
- Trained
- Jefferson Medical College of Thomas Jefferson University, 2007
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CO 94573255
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X); Medical oncology (207RX0202X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-07-03
- NPI last updated
- 2024-04-15
- NPI record certified
- 2024-04-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1804 Embarcadero Rd, Palo Alto, CA, 94303